U.S. Food and Drug Administration (FDA) approved AbbVie’s Imruvica (ibrutinib) combined rituximab (Rituxan) for treating adult patients with Waldenström’s macroglobulinemia (WM).Read more
@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie,Read more
AbbVie plans to it increase its earnings per share and elevates the market value of the remaining shares, as it has authorized a $5 billion increase to AbbVie’s existing stock repurchase program.Read more
AbbVie, the global research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories has declared a quarterly cash dividend of $0.64 per share.Read more
The fourth quarter was a continuation of the strong performance and business momentum AbbVie has delivered since becoming an independent company in 2013.Read more
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seekingRead more